Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 8/20 | 1.00 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.56 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.55 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.55 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4699888 | 0.84 | GRM5 (0.72) | GRM5 | |
| SCHEMBL4701228 | 0.84 | GRM5 (0.72) | GRM5 | |
| SCHEMBL4698743 | 0.80 | GRM5 (0.67) | GRM5 | |
| SCHEMBL4700157 | 0.80 | GRM5 (0.67) | GRM5 | |
| SCHEMBL2119703 | 0.79 | GRM5 (0.65) | GRM5CLK4CHRNB2CHRNA5CHRNA4 | |
| Hydrochloric Acid SCHEMBL2117989 | 0.78 | GRM5 (0.64) | GRM5CLK4CHRNB2CHRNA5CHRNA4 | |
| SCHEMBL13683872 | 0.78 | GRM5 (0.86) | GRM5 | |
| SCHEMBL5201721 | 0.78 | GRM5 (1.00) | GRM5CLK4ALDH1A1 | |
| SCHEMBL5204644 | 0.77 | GRM5 (1.00) | GRM5CLK4 | |
| SCHEMBL2118957 | 0.76 | CHRNB2 (0.82) | GRM5CLK4CHRNB2CHRNA5CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1434773-B1 | HETEROARYL SUBSTITUTED TETRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | MERCK & CO INC (US) | 2008-05-21 | — | — | EP | claimed |
| US-7253190-B2 | Heteroaryl substituted tetrazole modulators of metabotrophic glutamate receptor-5 | MERCK & CO., INC. (US) | 2007-08-07 | — | — | US | claimed |
| EP-1434773-A4 | HETEROARYL SUBSTITUTED TETRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | MERCK & CO INC (US) | 2005-01-12 | — | — | EP | claimed |
| US-20040186295-A1 | Heteroaryl substituted tetrazole modulators of metabotrophic glutamate receptor-5 | MERCK SHARP & DOHME LLC | 2004-09-23 | — | — | US | claimed |
| EP-1434773-A2 | HETEROARYL SUBSTITUTED TETRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | Merck & Co., Inc. (US) | 2004-07-07 | — | — | EP | claimed |
| WO-2004030637-A2 | TREATMENT OF OBESITY AND OTHER DISORDERS ASSOCIATED WITH EXCESSIVE FOOD INTAKE | MERCK & CO., INC. (US) | 2004-04-15 | — | — | WO | claimed |
| WO-2003029210-A2 | HETEROARYL SUBSTITUTED TETRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | MERCK & CO. INC. (US) | 2003-04-10 | — | — | WO | claimed |
| EP-1434773-B1 | HETEROARYL SUBSTITUTED TETRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | MERCK & CO INC (US) | 2008-05-21 | — | — | EP | disclosed |
| US-7253190-B2 | Heteroaryl substituted tetrazole modulators of metabotrophic glutamate receptor-5 | MERCK & CO., INC. (US) | 2007-08-07 | — | — | US | disclosed |
| EP-1434773-A4 | HETEROARYL SUBSTITUTED TETRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | MERCK & CO INC (US) | 2005-01-12 | — | — | EP | disclosed |
| US-20040186295-A1 | Heteroaryl substituted tetrazole modulators of metabotrophic glutamate receptor-5 | MERCK SHARP & DOHME LLC | 2004-09-23 | — | — | US | disclosed |
| EP-1434773-A2 | HETEROARYL SUBSTITUTED TETRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | Merck & Co., Inc. (US) | 2004-07-07 | — | — | EP | disclosed |
| WO-2004030637-A2 | TREATMENT OF OBESITY AND OTHER DISORDERS ASSOCIATED WITH EXCESSIVE FOOD INTAKE | MERCK & CO., INC. (US) | 2004-04-15 | — | — | WO | disclosed |
| WO-2003029210-A2 | HETEROARYL SUBSTITUTED TETRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | MERCK & CO. INC. (US) | 2003-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186295-A1 | Heteroaryl substituted tetrazole modulators of metabotrophic glutamate receptor-5 | GRM5, GRM1, GRIK5 | GRM5 1/4885CLK4 908/4885CHRNB2 535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.